Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100893 · ClinicalTrials.gov registry record · Phase 1
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00100893 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 37 participants.
The verdict
NCT00100893, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of IH636 grape seed extract may prevent breast cancer. PURPOSE: This phase I trial is studying the side effects and best dose of IH636 grape seed extract in preventing breast cancer in postmenopausal women at risk of developing breast cancer.
Interventions
- DIETARY_SUPPLEMENT IH636 grape seed proanthocyanidin extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-01 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100893
The ClinicalTrials.gov registry entry for NCT00100893 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IH636 grape seed proanthocyanidin extract is the first listed.
NCT00100893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100893 about?
NCT00100893 is a clinical study titled "IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of IH636 grape seed extract may prevent breast cancer. PURPOSE: This phase I trial is studying the side effects and best dose of IH636 grape seed extract in preventing breast cancer ...
What is the current status of trial NCT00100893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2005-01. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00100893?
The interventions under investigation include: IH636 grape seed proanthocyanidin extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00100893?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.